Latest News

CHAIN Awarded £0.5M Grant Funding to Develop Healthcare Platform

CHAIN Biotech has been awarded £0.5M grant funding from Innovate UK, the UK’s innovation agency, to expand its range of biotechnology products. Building on a successful synthetic biology program, are centered on enhancing and extending the capability of CHAIN’s proprietary Clostridium spore-based delivery platform for therapeutic and specialty chemical applications.

A two-year project will focus on the development of novel therapeutic peptides targeting gut-related disease. CHAIN has successfully demonstrated the use of Clostridium to deliver small molecules to the gut. In this project, we will expand the range of therapeutics to include anti-microbial and anti-inflammatory peptides. This work will be carried out in collaboration with leading researchers in Clostridium genetics at the Synthetic Biology Research Centre (SBRC) at the University of Nottingham.

The second project focuses on the production of high-value chiral chemicals. CHAIN has already successfully developed a Clostridium strain that produces (R)-1,3 butanediol, an important building block for several nutraceutical and pharmaceutical products. In this project, we plan to improve microbial performance and deliver a cost-completive fermentation process for chemical production.

CHAIN is currently focused on the testing and progression of its lead gut microbiome therapeutic for the clinic, targeting inflammatory bowel disease.

Dr Edward Green, Chief Executive at CHAIN comments:
“Grant funding supports our highly skilled discovery team, based at the SBRC, and strengthens ties with the Centre. Ultimately, this serves to build and accelerate our product discovery pipeline without undue distraction from our lead product.”

Synthetic Biology Research Centre, University of Nottingham

Related News

CHAIN Appoints New Board Members

CHAIN welcomes to its Board of Directors the recent appointment of Dr Mike McDonald...

CHAIN Finalists in Biotechnology Awards

CHAIN Biotechnology is proud to announce that it is a finalist in two competitions...

CHAIN Celebrates Successful ‘Chiral Chemical Synthesis in Clostridia’ Study

LONDON, UK, 10 AUGUST 2016 -- CHAIN Biotechnology Ltd has successfully completed a 12-month...

omega 3 nutritional supplements
CHAIN Obtains Grant Funding For Collaborative Projects

June 11, 2016 – London, UK. CHAIN Biotechnology Ltd has won grant funding for...

CHAIN new employees clostridium modular vectors omega 3
CHAIN Welcomes New Starters

CHAIN has hired two new world class scientific team members to expand its role...

CHAIN Secures Seed Funding and Appoints New Board Members

London, UK, 23 December, 2015 CHAIN has successfully completed its first round of seed funding...

CHAIN HPLC Analysis of Chiral Chemicals Innovate UK feasibility study for Collaboration Nation: synthetic biology and strain development of anaerobic bacteria
CHAIN Celebrates Feasibility Study Success at Collaboration Nation

CHAIN Biotech has successfully completed a feasibility study into altering bacterial metabolism to produce...

CHAIN Wins Business Interaction Voucher for clostridia strain development
CHAIN Wins Business Interaction Voucher with University of Nottingham

CHAIN Biotechnology has been awarded a £5,000 Business Interaction Voucher in partnership with the...

CHAIN launches a new grant funded research project

CHAIN has been awarded £180K from InnovateUK for a project focused on the production...

CHAIN wins award and launches new website

Award winning CHAIN Biotech launches its new website, funded by a prize voucher from...

CHAIN joins University of Nottingham Synthetic Biology Research Centre

CHAIN Biotechnology Ltd is proud to announce a new collaboration with Professor Nigel Minton’s...

CHAIN hires Research Manager

CHAIN Biotechnology Ltd welcomes Dr Dana Heldt. Dana is an experienced strain development scientist...